Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1991 1
1997 1
2002 2
2003 5
2004 4
2005 6
2006 4
2007 3
2008 7
2009 6
2010 6
2011 10
2012 10
2013 13
2014 10
2015 16
2016 9
2017 17
2018 22
2019 31
2020 35
2021 30
2022 29
2023 22

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Results by year

Filters applied: . Clear all
Page 1
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: riganti c. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.
Hypoxia as a driver of resistance to immunotherapy.
Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Kopecka J, et al. Among authors: riganti c. Drug Resist Updat. 2021 Dec;59:100787. doi: 10.1016/j.drup.2021.100787. Epub 2021 Nov 18. Drug Resist Updat. 2021. PMID: 34840068 Free article. Review.
Impact of cancer metabolism on therapy resistance - Clinical implications.
Gonçalves AC, Richiardone E, Jorge J, Polónia B, Xavier CPR, Salaroglio IC, Riganti C, Vasconcelos MH, Corbet C, Sarmento-Ribeiro AB. Gonçalves AC, et al. Among authors: riganti c. Drug Resist Updat. 2021 Dec;59:100797. doi: 10.1016/j.drup.2021.100797. Epub 2021 Dec 16. Drug Resist Updat. 2021. PMID: 34955385 Free article. Review.
Doxorubicin-antioxidant co-drugs.
Chegaev K, Riganti C, Rolando B, Lazzarato L, Gazzano E, Guglielmo S, Ghigo D, Fruttero R, Gasco A. Chegaev K, et al. Among authors: riganti c. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5307-10. doi: 10.1016/j.bmcl.2013.07.070. Epub 2013 Aug 8. Bioorg Med Chem Lett. 2013. PMID: 23973213 Free article.
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.
Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. Salaroglio IC, et al. Among authors: riganti c. Int J Mol Sci. 2019 May 21;20(10):2505. doi: 10.3390/ijms20102505. Int J Mol Sci. 2019. PMID: 31117237 Free PMC article. Review.
267 results